Director, HCP Marketing

Bothell, WA (On-site)

$198K/yr – $252K/yrDirector/Executive10+ years expFull time

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive the U.S. HCP promotion for varegacestat with end-to-end launch ownership, compliant messaging, and field enablement, guiding cross-functional teams to achieve launch readiness and compliant, impactful medical marketing.

  • Must-have: Oncology launch experience with proven, compliant storytelling
  • Standout: Strong cross-functional leadership and ability to coordinate across agencies

Job Description

Responsibilities

  • Lead the U.S. HCP promotional strategy for Varegacestat, ensuring alignment to overall brand strategy and evolving market dynamics
  • Develop and maintain HCP positioning, core narrative, messaging architecture, and claims strategy grounded in customer insights and clinical evidence
  • Translate market research, competitive intelligence, and field feedback into clear, actionable strategic briefs that guide creative development and promotional execution
  • Define success metrics for HCP promotion (e.g., message pull-through, call effectiveness, material utilization) and drive continuous improvement based on performance insights
  • Lead development of the unbranded DSE plan to build pre-launch market readiness
  • Lead development of personal promotion assets and field resources to enable high-impact engagements
  • Drive end-to-end execution from concept through approval, production, and deployment—ensuring high quality, on-time delivery, and practical usability in the field
  • Partner with MLR/PRC to ensure materials are compliant, accurate, balanced, and consistent with FDA regulations, OPDP expectations, and Immunome standards
  • Lead the field advisory committee and translate learnings into improvements across messaging, materials, and execution
  • Partner with Sales and Sales Training to build launch and ongoing training that reinforces the brand story, clinical narrative, and compliant message delivery

Requirements

  • Bachelor’s degree required; Advanced degree (e.g., PharmD, MBA) preferred
  • A minimum of 10 years of experience in pharmaceutical, biotech, or healthcare marketing, with a strong focus on HCP marketing
  • Oncology launch experience required
  • Oncology sales experience preferred
  • Proven track record translating clinical data into compelling, compliant promotional narratives, messaging frameworks, and creative direction
  • Strong understanding of MLR/PRC processes, claims substantiation, and OPDP regulations
  • Demonstrated ability to thrive in a fast-paced biotech environment
  • Ability to travel ≥30%, including occasional weekends
  • Deep knowledge of U.S. HCP promotion and field sales dynamics, including the realities of call execution and the drivers of field adoption
  • Ability to build clear, differentiated messaging and equip the field with tools that are clinically credible, customer-relevant, and compliant

Preferred

  • Advanced degree (e.g., PharmD, MBA) preferred
  • Prior experience leading field/in-field marketing teams
  • Experience in biotech startup or entrepreneurial environment
Immunome, Inc. logo

Immunome, Inc.

2.5 Glassdoor

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Founded in 2008
Bothell, Washington, USA
187 employees (3 in marketing)
58% recommend to a friend

Traffic Signals

Monthly Visitors
12.4K
Traffic Source Mix
Search
31.1%
Direct
45.6%
Referral
6.5%
Social
15.2%
Paid
1.5%

Headcount Trend

Current headcount: ~191

Marketing Team

Marketing Team Size
3 (2% of company)

Funding

Total Funding
$998.9M
Last Raise
$400M
Post IPO Equity, 3 months ago

Funding History

  • Dec 2025
    Post IPO Equity • $400M
  • Jan 2025
    Post IPO Equity • $150M
  • Feb 2024
    Post IPO Equity • $230M

Recent News